+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Cancer Profiling Market - Forecasts From 2018 to 2023

  • ID: 4718375
  • Report
  • November 2018
  • Region: Global
  • 105 pages
  • Knowledge Sourcing Intelligence LLP
1 of 3


  • Caris Life Sciences
  • Genomic Health
  • Helomics Corp
  • Illumina, Inc.
  • Oxford Gene Technology
  • Qiagen
  • MORE
The global Cancer Profiling market is expected to reach US$14.223 billion by 2023 from US$7.109 billion in 2017 growing at a CAGR of 12.25%. Tumour or cancer profiling is done to get genetic information regarding the tumour cells which offer useful insights and information regarding the disease. Cancer profiling is done to aid in the selection of appropriate therapy for the treatment of cancer. The cancer provide more precise and accurate information about clinical outcomes of cancer. The technique plays a vital role in diagnosis of cancer at the molecular level. The market is expected to show significant growth during the given forecast period owing to the increasing prevalence of the cancer across the globe. Availability of the funding by the government and non-government organisation for the cancer research will also boost the market for cancer profiling. Increasing utility of cancer profiling to select the right therapy for the patients will also bolster the demand for cancer profiling. However, high investment required for the development of the biomarkers coupled with the lack of skilled professionals might restrain the growth the market during the given time frame.

This research study examines the current market trends related to the demand, supply, and sales, in addition to the recent developments. Major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented in each of the geographical region. Further, the overall regulatory framework of the market has been exhaustively covered to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Identification of key industry players in the industry and their revenue contribution to the overall business or relevant segment aligned to the study have been covered as a part of competitive intelligence done through extensive secondary research. Various studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research. Both bottom-up and top down approaches have been utilized to determine the market size of the overall market and key segments. The values obtained are correlated with the primary inputs of the key stakeholders in the global Cancer Profiling market value chain. Last step involves complete market engineering which includes analysing the data from different sources and existing proprietary datasets while using various data triangulation methods for market breakdown and forecasting.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the global Cancer Profiling market.

Major industry players profiled as part of the report are Medtronic, Abbott and NDI Medical among others.


By Technique

Fluorescence in situ Hybridization (FISH)
Next-Generation Sequencing (NGS)
Quantitative Polymerase Chain Reaction (qPCR)

By Cancer Type

Lung Cancer
Breast Cancer
Bowel Cancer

By End User

Hospitals and Clinics
Diagnostic Centres

By Geography

North America
United States

South America

United Kingdom

Middle East and Africa
Saudi Arabia

Asia Pacific
South Korea
Note: Product cover images may vary from those shown
2 of 3


  • Caris Life Sciences
  • Genomic Health
  • Helomics Corp
  • Illumina, Inc.
  • Oxford Gene Technology
  • Qiagen
  • MORE
1. Introduction
1.1. Market Definition
1.2. Scope of the Study
1.3. Currency
1.4. Assumptions
1.5. Base, and Forecast Years Timeline

2. Research Methodology
2.1. Research Design
2.2. Secondary Sources
2.3. Validation

3. Key Findings of the Study

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities and Market Trends
4.4. Market Segmentation
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Competitive Rivalry in the Industry
4.6. Industry Value Chain Analysis
4.7. Industry Regulations
4.8. Scenario Analysis

5. Global Cancer Profiling Market Forecast by Techniques
5.1. Immunohistochemistry
5.2. Fluorescence in situ Hybridization (FISH)
5.3. Next-Generation Sequencing (NGS)
5.4. Quantitative Polymerase Chain Reaction (qPCR)

6. Global Cancer Profiling Market Forecast by Application
6.1. Lung Cancer
6.2. Breast Cancer
6.3. Bowel Cancer
6.4. Others

7. Global Cancer Profiling Market Forecast by End Users
7.1. Hospitals and Clinics
7.2. Diagnostic Centres

8. Global Cancer Profiling Market Forecast by Geography
8.1. North America
8.1.1. The U.S
8.1.2. Canada
8.1.3. Mexico
8.1.4. Others
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Others
8.3. Europe
8.3.1. U.K.
8.3.2. France
8.3.3. Germany
8.3.4. Italy
8.3.5. Others
8.4. Middle East and Africa
8.4.1. Saudi Arabia
8.4.2. UAE
8.4.3. Israel
8.4.4. Others
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Australia
8.5.4. South Korea
8.5.5. Others

9. Competitive intelligence
9.1. Market Share Analysis
9.2. Strategies of Key Players
9.3. Recent Investments and Deals

10. Company Profiles
10.1. Illumina, Inc.
10.1.1. Overview
10.1.2. Financials
10.1.3. Product and Services
10.1.4. Recent Developments
10.2. Qiagen
10.2.1. Overview
10.2.2. Financials
10.2.3. Product and Services
10.2.4. Recent Developments
10.3. NeoGenomics Laboratories, Inc.
10.3.1. Overview
10.3.2. Financials
10.3.3. Product and Services
10.3.4. Recent Developments
10.4. Ribomed
10.4.1. Overview
10.4.2. Financials
10.4.3. Product and Services
10.4.4. Recent Developments
10.5. NanoString Technologies, Inc.
10.5.1. Overview
10.5.2. Financials
10.5.3. Product and Services
10.5.4. Recent Developments
10.6. HTG Molecular Diagnostics, Inc.
10.6.1. Overview
10.6.2. Financials
10.6.3. Product and Services
10.6.4. Recent Developments
10.7. Caris Life Sciences
10.7.1. Overview
10.7.2. Financials
10.7.3. Product and Services
10.7.4. Recent Developments
10.8. Genomic Health
10.8.1. Overview
10.8.2. Financials
10.8.3. Product and Services
10.8.4. Recent Developments
10.9. Helomics Corp
10.9.1. Overview
10.9.2. Financials
10.9.3. Product and Services
10.9.4. Recent Developments
10.10. Oxford Gene Technology
10.10.1. Overview
10.10.2. Financials
10.10.3. Product and Services
10.10.4. Recent Developments
Note: Product cover images may vary from those shown
3 of 3
  • Illumina, Inc.
  • Qiagen
  • NeoGenomics Laboratories, Inc.
  • Ribomed
  • NanoString Technologies, Inc.
  • HTG Molecular Diagnostics, Inc.
  • Caris Life Sciences
  • Genomic Health
  • Helomics Corp
  • Oxford Gene Technology
Note: Product cover images may vary from those shown